MAAD: multidimensional antiviral antibody database
Protein & Cell · 2025
DOI: 10.1093/procel/pwaf106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein & Cell, 2025. Verfasst von Yixin Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. Hauptthemen laut MEDLINE: Antibodies, Viral, Databases, Protein, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Strategic Priority Research Program, National Natural Science Foundation of China, Basic Research Program Based on Major Scientific Infrastructures.
Abstract (Originalsprache)
Antibodies have emerged as central components of therapeutic strategies against viral infectious diseases, functioning as key effectors in both prevention and treatment. While traditional antibody discovery has relied heavily on high-throughput screening, the field is now shifting toward rational antibody design, which requires integrative insights into sequence–structure–function relationships. However, existing resources provide a valuable foundation but remain limited in scope, highlighting the need for a standardized and well-annotated antibody database that integrates multidimensional features to further support systematic exploration, cross-pathogen comparison, and rational antibody design. Here, we introduce the Multidimensional Antiviral Antibody Database (MAAD; raabmd.org/raab/index), a curated platform dedicated to antibody, nanobody and single-chain variable fragment targeting three high-impact RNA virus families, Coronaviridae (SARS-CoV-1, SARS-CoV-2, MERS-CoV), Orthomyxoviridae (influenza virus), and Pneumoviridae (respiratory syncytial virus, human metapneumovirus), which were selected due to the large, high-quality datasets accumulated in recent years. MAAD further incorporates a suite of interactive analysis modules, including CDR and germline annotation, similarity-based sequence analysis, sequence-based clustering and structure-guided identification of antigen–antibody interface residues, complemented by per-site entropy and mutation rate profiling. These features enable in-depth exploration of antibody sequence characteristics, thereby facilitating functional and structural insights for rational antibody design. Together, by bridging antibody sequence, structure, and function, MAAD offers an open and standardized platform that advances comparative antiviral research and supports therapeutic antibody discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Changping Laboratory, Beijing 102206, China.
ORCID-Profile: Yixin Li, Jinyue Wang, Yuxia Zhang, Xiangxi Wang
Förderung
- Strategic Priority Research Program
- National Natural Science Foundation of China
- Basic Research Program Based on Major Scientific Infrastructures
- National Key Research and Development Program
- National Natural Science Foundation of China Youth Science Foundation Project
- National Science and Technology Major Project
- New Cornerstone Science Foundation
Zitieren
APA
Li, Y., Wang, J., Zhang, C., Zhang, Y., Deng, J., Zhang, H., Li, M., Wang, F., & Wang, X. (2025). MAAD: multidimensional antiviral antibody database. Protein & Cell. https://doi.org/10.1093/procel/pwaf106
Vancouver
Li Y, Wang J, Zhang C, Zhang Y, Deng J, Zhang H, et al. MAAD: multidimensional antiviral antibody database. Protein & Cell. 2025. doi:10.1093/procel/pwaf106
BibTeX
@article{Li2025,
author = {Li, Yixin and Wang, Jinyue and Zhang, Chuziyue and Zhang, Yuxia and Deng, Jie and Zhang, Han and Li, Mingkai and Wang, Fan and Wang, Xiangxi},
title = {MAAD: multidimensional antiviral antibody database},
journal = {Protein & Cell},
year = {2025},
doi = {10.1093/procel/pwaf106}
}
EUVIMED